Abstracts Archive - Page 674 of 2607 - ACR Meeting Abstracts

Abstract Number: PP09 • ACR Convergence 2022
A Matter of Life and Death: Why Diversity, Equity and Inclusion Matter for Health Care Providers
Tonya Horton, Rutgers University, Cherry Hill, NJ
Background/Purpose: In 2017, I went from exercising daily to hardly able to walk due to severe knee pain. My primary care doctor ordered x-rays and…
Abstract Number: 2275 • ACR Convergence 2022
Three Dose SARS-CoV-2 Vaccination Is Associated with Reduced Risk of Breakthrough COVID-19 During Omicron Wave in Patients with Autoimmune Diseases
Caoilfhionn Connolly¹, Rachel Wallwork¹, Teresa Po-Yu Chiang¹, Mayan Teles¹, Jennifer Alejo¹, Allan Massie², Ami Shah³, Jemima Albayda¹, Lisa Christopher-Stine¹, Dorry Segev², William Werbel¹ and Julie Paik¹, ¹Johns Hopkins University, Baltimore, MD, ²NYU Langone Health, New York, NY, ³Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: While SARS-CoV-2 vaccination mitigates the risk of severe COVID-19, vaccinated patients with autoimmune diseases are more susceptible to infection despite vaccination ("breakthrough" COVID-19) and…
Abstract Number: PP11 • ACR Convergence 2022
Exercise as a Supportive Treatment for My Ankylosing Spondylitis
Sara King-Dowling, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Patients with autoimmune rheumatic diseases (ARDs) are often caught in a paradox as they experience mobility challenges, but long periods of immobility cause increased…
Abstract Number: PP15 • ACR Convergence 2022
Coordination of Care by a Healthcare Team for Unexpected and Unusual Side Effects Occurring During a Global Pandemic
Laura Genoves, Arthritis Foundation, Bainbridge Island, WA
Background/Purpose: I am a patient who lives with moderate to severe RA. My quality of life is dependent on medications such as a biologic, DMARDs…
Abstract Number: PP13 • ACR Convergence 2022
How Becoming Engaged in My Care with Specialized Tools and Support Helped Me Find My Personal Lupus Triggers and Regain Control of My Health
Tonya Hinton-Green, Philadelphia, PA
Background/Purpose: My story begins in the ER where I was diagnosed with lupus right after my 22nd birthday.For the next 25 years I went from…
Abstract Number: PP18 • ACR Convergence 2022
From Devastated to Empowered: How Patient Engagement in Research Changes Lives
Eileen Davidson, Burnaby, BC, Canada
Background/Purpose: In April of 2015 I was a 29 year-old single mom diagnosed with rheumatoid arthritis (RA). RA wasn't unknown to me; my aunt who…
Abstract Number: PP17 • ACR Convergence 2022
Engaging with the Spoon Theory: How I Make Decisions Using a Cost-Benefit Analysis That Works to Improve My Mental Health While Living with RA
Stephanie Aleite, AiArthritis, St. Louis, MO
Background/Purpose: Patients living with rheumatoid arthritis (RA) often also live with comorbid mental health conditions. Regardless of diagnosed mental health condition, living with a chronic…
Abstract Number: PP19 • ACR Convergence 2022
Living with Rheumatoid Arthritis in a Rural Farming Community: How I Found a Rheumatologist and Got Targeted Treatment
Vanessa Kerr, Mexico, MO
Background/Purpose: I'm Vanessa and I've been married to James, a farmer, for 27 years. We have 5 children and when my fourth was born, I…
Abstract Number: PP16 • ACR Convergence 2022
Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis
Ashley Krivohlavek, Oklahoma City, OK
Background/Purpose: At age 12, I was diagnosed with psoriasis (PsO) followed by a diagnosis of psoriatic arthritis (PsA) at age 30. I'm now 38. In…
Abstract Number: 2273 • ACR Convergence 2022
Waning Vaccine Response After Primary Vaccine Series: Results from the Covid19 Vaccine Response in Rheumatology Patients (COVER) Study
Amy Mudano¹, Gary Cutter², Ted Mikuls³, Geoffrey Thiele⁴, Mark Law⁴, Bart Hamilton⁴, Michael Zikry⁵, Kelly Y. Chun⁶, Monique Bastidas⁷, Michael George⁸, Lisa Williams⁹, Kevin Winthrop¹⁰, Mark Busch¹¹, Stanley Cohen¹², Roman Czubatyj¹³, Rajesh Kataria¹⁴, Reshma Khan¹⁵, Soha Mousa¹⁶, Jose Pando¹⁷, Elizabeth Perkins¹⁸, Shanmugapriya Reddy¹⁹, Delfin Santos²⁰, Joy Schechtman²¹, Frank Scott²², Sucharitha Shanmugam²³, Atul Singhal²⁴, John Tesser²⁵, John Tower²⁶, Swamy Venuturupalli²⁷, Sean Joseph Wollaston²⁸, Conrad Ziembinski²⁹ and Jeffrey Curtis³⁰, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵LabCorp, Burlington, NC, ⁶Labcorp, Calabasas, CA, ⁷LabCorp, Northridge, CA, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Illumination Heath, Hoover, AL, ¹⁰Oregon Health & Science University, Portland, OR, ¹¹Family Arthritis Center-Jupiter, Jupiter, FL, ¹²Metroplex Clinical Research Center, Pittsburgh, PA, ¹³Arthritis Physicians LLC, Rochester Hills, MI, ¹⁴Southern Ohio, Wheelersburg, OH, ¹⁵Palm Beach Rheumatology and Wellness, Jupiter, FL, ¹⁶Arthritis and Rheumatology of Southwest Ohio, Liberty Township, OH, ¹⁷Rheumatology Consultants of DE, Lewes, DE, ¹⁸Rheumatology Care Center, Hoover, AL, ¹⁹Southwest Florida Rheumatology, Riverview, FL, ²⁰Rochester Rheumatology, Rochester Hills, MI, ²¹SunValley Arthritis Center, Peoria, AZ, ²²Arthritis Medical Center, Arroyo Grande, CA, ²³Rheumatology and Arthritis Care Center, Exton, PA, ²⁴Southwest Rheumatology Research, Mesquite, TX, ²⁵Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²⁶Arthritis Physicians LLC, Rochester, MI, ²⁷Cedars-Sinai Medical Center, Los Angeles, CA, ²⁸Rheumatology Associates, North Hollywood, CA, ²⁹CZ Rheumatology, Coral Springs, FL, ³⁰Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Given possible increased risk of COVID-19 in patients with autoimmune conditions, there is a need to better understand the immunogenicity and safety of SARS-CoV-2…
Abstract Number: PP23 • ACR Convergence 2022
The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient
Amy Gietzen and Hannah Bowen, The Ann Steffens Scleroderma Foundation, Albany, NY
Background/Purpose: In 2001 I started to experience forearm, elbow, and wrist pain. My fingers were constantly swollen, and sensitive. After 6 months of living in…
Abstract Number: PP25 • ACR Convergence 2022
From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective
Shung Chiu¹ and Mei Nee Chiu², ¹Spondylitis Association of America, Ludhiana, Punjab, India, ²University Institute of Pharmaceutical Sciences, Panjab University, Ludhiana, Punjab, India
Background/Purpose: From being a table tennis champion to getting into medical school, I thought my life was smooth sailing. But little did I know it…
Abstract Number: PP21 • ACR Convergence 2022
What Lies Beneath: Making Rheumatoid Arthritis Visible for the Seronegative Patient Through Blood Work
Shilpa Venkatachalam, Global Healthy Living Foundation, New York, NY
Background/Purpose: When I first received my Rheumatoid Arthritis (RA) diagnosis 5 years ago, I experienced a combination of relief and disbelief. Relief because now all…
Abstract Number: 2272 • ACR Convergence 2022
Temporal Trends in COVID-19 Outcomes Among Patients with Systemic Autoimmune Rheumatic Diseases: From the First Wave to Omicron
Yumeko Kawano¹, Naomi Patel², Xiaosong Wang¹, Claire Cook³, Kathleen Vanni¹, Emily Kowalski¹, Emily Banasiak¹, Grace Qian¹, Michael Diiorio¹, Tiffany Hsu¹, Michael Weinblatt⁴, Derrick Todd¹, Zachary Wallace³ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Sale Creek, TN, ³Massachusetts General Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Advances in prevention, testing, and treatment of COVID-19 have contributed to less severe outcomes in the general population, but whether outcomes have improved for…
Abstract Number: 2128 • ACR Convergence 2022
Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics
Iain B McInnes¹, John Tesser², Elena Schiopu³, Joseph Merola⁴, Soumya Chakravarty⁵, Emmanouil Rampakakis⁶, Natalie Shiff⁷, Alexa Kollmeier⁸, Xie L Xu⁹, May Shawi¹⁰, Frederic Lavie¹¹, Paul Bird¹² and Philip J Mease¹³, ¹Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ²Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ³Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Villanova, PA, ⁶McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ⁷Janssen Scientific Affairs, LLC; Community Health and Epidemiology, University of Saskatchewan, Philadelphia, PA, ⁸Janssen-Cilag, Research & Development, LLC, San Diego, CA, ⁹Janssen Research & Development, LLC, San Diego, CA, USA, San Marcos, CA, ¹⁰Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ¹¹The Janssen Pharmaceutical Companies of Johnson & Johnson, Paris, France, Paris, France, ¹²University of New South Wales, Sydney, Australia, ¹³Swedish Medical Center/Providence St. Joseph Health, Seattle, WA
Background/Purpose: In the phase 3 DISCOVER (D)-1 and D-2 studies, guselkumab (GUS) significantly improved joint symptoms, skin disease, enthesitis, dactylitis, physical function, and quality of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].